OncoMatch/Clinical Trials/NCT06008054
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Is NCT06008054 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SI-B003 and BL-B01D1 for esophageal cancer.
Treatment: SI-B003 · BL-B01D1 · PD-1 Monoclonal Antibody — This phase II study is a clinical study to explore the efficacy and safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in patients with locally advanced or metastatic esophageal cancer, gastric cancer, colorectal cancer and other gastrointestinal tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Gastric Cancer
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antitumor therapy (chemotherapy or biological therapy)
Antitumor therapy such as chemotherapy or biological therapy was used within 4 weeks or 5 half-lives before the first dose in this study
Cannot have received: mitomycin (mitomycin)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: nitrosoureas (nitrosoureas)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: oral fluorouracil (fluorouracil)
Oral drugs such as fluorouracil
Cannot have received: antibody-drug conjugate
Exception: Cohort using BL-B01D1, previously treated with an ADC drug with topoisomerase I inhibitor as toxin
Cohort using BL-B01D1, previously treated with an ADC drug with topoisomerase I inhibitor as toxin
Cannot have received: immunomodulatory drugs
Immunomodulatory drugs were administered within 2 weeks before the first dose in this study
Lab requirements
Cardiac function
no severe cardiac dysfunction, left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify